The Valley Desk

ArticleJournal of medical economicsPublished

Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Journal of medical economics
Published
Subject terms
Humans; Carcinoma in Situ; Antineoplastic Agents; BCG Vaccine; Administration, Intravesical; United States Food and Drug Administration; Aged; Medicare; United States; Female; Male; Urinary Bladder Neoplasms
PubMed ID
42012856
Added to directory
Source checked

Report a correction or request removal